Multiple Sclerosis
📧 Sign up to get email alerts when something new happens for Multiple Sclerosis.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2019-12-27FDA Approved: COPAXONE — Supplemental Application (Teva Neuroscience, Inc.)
The FDA approved a supplemental application for COPAXONE (glatiramer acetate) from Teva Neuroscience, Inc., indicating regulatory action on …
-
FDA approval · 2019-12-26FDA Approved: GILENYA — Supplemental Application (Novartis Pharmaceuticals Corporation)
FDA approved a supplemental application for GILENYA (fingolimod HCl) submitted by Novartis Pharmaceuticals Corporation.
-
FDA label_change · 2019-12-19FDA Approved: AMPYRA — Supplemental Application (Merz Pharmaceuticals, LLC)
FDA approved a supplemental application for AMPYRA (dalfampridine) submitted by Merz Pharmaceuticals, LLC. The action entails a labeling cha…
-
CLINICAL_TRIALS trial_result · 2019-12-12Clinical Trial Update: Investigation of Simvastatin in Secondary Progressive Multiple Sclerosis [Phase 2]
A Phase 2 trial investigated simvastatin for secondary progressive multiple sclerosis; the study has completed and results were posted in 20…
-
FDA approval · 2019-12-11FDA Approved: TECFIDERA — Supplemental Application (Biogen Inc.)
The FDA approved Biogen's supplemental application for Tecfidera (dimethyl fumarate).
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2019-12-04Clinical Trial Update: Long-Term Extension Study in Participants With Multiple Sclerosis Who Have Completed Study 205MS301 (NCT01064401) to Evaluate the Safety and Efficacy of BIIB019 [Phase 3]
Long-term extension study in multiple sclerosis participants completed following a prior trial; terminated with results posted in 2019.
-
FDA approval · 2019-12-04FDA Approved: FINGOLIMOD — Original Application (Sun Pharmaceutical Industries, Inc.)
FDA approves Sun Pharmaceutical's original application for fingolimod (generic) for relapsing forms of multiple sclerosis.
-
FDA approval · 2019-12-04FDA Approved: FINGOLIMOD — Original Application (Quallent Pharmaceuticals Health LLC)
FDA approved fingolimod as an original application (generic) submitted by Quallent Pharmaceuticals Health LLC.
-
FDA approval · 2019-11-29FDA Approved: TERIFLUNOMIDE — Supplemental Application (Aurobindo Pharma Limited)
FDA approved a supplemental application for a generic version of teriflunomide, manufactured by Aurobindo Pharma Limited (ANDA 209638).
-
FDA approval · 2019-11-29FDA Approved: TERIFLUNOMIDE — Supplemental Application (Glenmark Pharmaceuticals Inc., USA)
FDA approved a supplemental application for teriflunomide by Glenmark Pharmaceuticals Inc., USA. Teriflunomide is a disease-modifying therap…
-
CLINICAL_TRIALS trial_result · 2019-11-22Clinical Trial Update: Extension Study of BG00012 in Pediatric Subjects With Relapsing Remitting Multiple Sclerosis (RRMS) [Phase 3]
Phase 3 extension study in pediatric relapsing-remitting multiple sclerosis completed; results posted in 2019.
-
CLINICAL_TRIALS trial_result · 2019-11-22Clinical Trial Update: Testosterone Treatment for Multiple Sclerosis [Phase 1, Phase 2]
Clinical trial update on testosterone treatment for multiple sclerosis (Phase 1/2) completed with results posted.
-
EMA safety_alert · 2019-11-15Measures to minimise risk of serious side effects of multiple sclerosis medicine Lemtrada
EMA outlines measures to minimise serious side effects associated with Lemtrada (alemtuzumab) for multiple sclerosis, focusing on safety mon…
-
CLINICAL_TRIALS trial_result · 2019-11-15Clinical Trial Update: Prospective Observational Long-term Safety Registry of Multiple Sclerosis Participants Who Have Participated in Cladribine Clinical Trials
A long-term safety registry observational study following multiple sclerosis participants who previously took cladribine, with completed sta…
-
CLINICAL_TRIALS trial_result · 2019-11-06Clinical Trial Update: IPX056 in Subjects With Established Spasticity Resulting From Multiple Sclerosis [Phase 3]
Phase 3 clinical trial updating results for IPX056 in established spasticity due to multiple sclerosis.
-
CLINICAL_TRIALS trial_result · 2019-11-06Clinical Trial Update: A Study With IPX056 in Subjects With Spasticity Associated With Multiple Sclerosis [Phase 2]
A Phase 2 clinical trial evaluating IPX056 for spasticity in subjects with multiple sclerosis has completed.
-
CLINICAL_TRIALS trial_result · 2019-10-31Clinical Trial Update: Impact of Ketone Bodies and Epigallocatechin Gallate in Multiple Sclerosis [Phase 2]
Phase 2 trial investigating ketone bodies and epigallocatechin gallate in multiple sclerosis has completed.
-
CLINICAL_TRIALS trial_result · 2019-10-30Clinical Trial Update: Telephone-Delivered Exercise for Multiple Sclerosis Fatigue [NA]
Completed clinical trial evaluating telephone-delivered exercise to alleviate fatigue in multiple sclerosis.
-
FDA approval · 2019-10-29FDA Approved: VUMERITY — Original Application (Biogen Inc.)
The FDA approved Biogen's VUMERITY (diroximel fumarate) through its original NDA (NDA 211855). This approval supports use of diroximel fumar…
-
CLINICAL_TRIALS trial_result · 2019-10-15Clinical Trial Update: Trial of Memantine for Cognitive Impairment in Multiple Sclerosis [Phase 2, Phase 3]
A completed clinical trial evaluating memantine for cognitive impairment in multiple sclerosis (Phase 2/3).
-
CLINICAL_TRIALS trial_result · 2019-10-09Clinical Trial Update: Safety and Tolerability of Quetiapine in Multiple Sclerosis [Phase 1, Phase 2]
Phase 1/2 trial assessing safety and tolerability of quetiapine in patients with multiple sclerosis has completed.
-
CLINICAL_TRIALS trial_result · 2019-09-30Clinical Trial Update: Effects of Functional Electrical Stimulation Cycling Versus Cycling Only on Walking and Quality of Life in MS [NA]
A completed clinical trial compared functional electrical stimulation cycling to cycling alone for walking and quality of life in people wit…
-
FDA approval · 2019-09-27FDA Approved: DALFAMPRIDINE — Supplemental Application (Aurobindo Pharma Limited)
The FDA approved a supplemental application from Aurobindo Pharma Limited for dalfampridine, enabling the generic product to be marketed in …
-
CLINICAL_TRIALS trial_result · 2019-09-23Clinical Trial Update: STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START) [Phase 4]
Phase 4 trial evaluating telemetric ECG systems for first dose administration of fingolimod in multiple sclerosis; study completed with resu…
-
FDA approval · 2019-09-18FDA Approved: BACLOFEN — Original Application (Palmetto Pharmaceuticals Inc.)
FDA records an original application approval for Baclofen submitted by Palmetto Pharmaceuticals Inc. The document marks the approval of a Ba…